JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ: ABUS) after data presentation at the European Association for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback